Compare Hormel Foods Corp (HRL) vs Regeneron Pharmaceuticals Inc (REGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Hormel Foods Corp vs Regeneron Pharmaceuticals Inc — how do they compare? Hormel Foods Corp trades at $25.08 (market cap $13.91B), while Regeneron Pharmaceuticals Inc trades at $672.43 (market cap $70.47B). The key difference: Regeneron Pharmaceuticals Inc is far larger — about 5.1× Hormel Foods Corp's market cap, and Hormel Foods Corp pays the higher dividend (4.63%). Which is the better fit depends on your goals.
| HRL | REGN | |
|---|---|---|
Market Cap | $13.91B | $70.47B |
Sector | Consumer Staples | Health |
52-Week High | $29.52 | $812.27 |
52-Week Low | $19.74 | $545.46 |
Enterprise Value | $15.91B | $64.42B |
Dividend Yield | 4.63% | 0.56% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Hormel Foods (HRL) trades at $25.31, down 0.33% on the day, with a bullish technical outlook and consistent earnings beats. The stock shows a P/E of 29.87 and net income margin of 3.82%, supported by a recent dividend of $0.29. Revenue for 2025 was $12.11B, though net income declined to $478.20M. Analysts maintain a mixed consensus with a $26.33 price target, while the company focuses on portfolio streamlining, such as the sale of its Ceratti business in Brazil (PRNewsWire, 2026-06-29).
HRL offers a stable dividend yield and is near multi-year lows, presenting a value opportunity amid sector weakness. Risks include margin pressure from input costs and competitive threats in the consumer staples space. Institutional sentiment is cautious with 57% hold ratings, but technical indicators suggest potential upside if earnings momentum continues.
Regeneron Pharmaceuticals (REGN) trades at $671.9, down 0.71% on the day, with a bullish technical signal and strong fundamentals. The stock shows robust profitability with a 29.65% net income margin and consistent earnings beats in recent quarters. Analyst consensus is strongly bullish with a $764.50 price target, though recent news highlights a securities class action lawsuit filed in July 2026.
Outlook remains positive due to solid financials and analyst support, but risks include legal uncertainties from ongoing litigation and potential market volatility. The stock offers value with a P/E of 16.52, trading below the consensus target, presenting upside if legal concerns resolve favorably.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Hormel Foods Corp
Hormel Foods is a protein-focused branded food company. Its brands include its namesake Hormel, Spam, Jennie-O, Dinty Moore, Applegate, Wholly Guacamole, and Skippy. The vast majority of the company's revenue is U.S.-based: 64% U.S. retail, 28% U.S. food service, and 8% international. By product type, in fiscal 2021, 23% of revenue was shelf-stable foods, 18% was poultry (branded and commodity), 55% was other perishable food, and 3% was other, primarily nutritional products. The company holds the number-one market position in shelf-stable meat, shelf-stable ready meals, pepperoni, natural/organic deli meat, and guacamole and the number-two position in turkey, bacon, chilled ready meals, and peanut butter.
Read more on HRL →About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →
